Founder and Chief Strategy Officer
Tom Farrell has a 20-year track record as a biotech entrepreneur. He was most recently President and CEO of Bellicum Pharmaceuticals, a pioneer in the development of controllable cell therapies. At Bellicum, which he built from a virtual startup through a highly successful IPO in 2014, raising a total of more than $300 million in the process, Tom brought five genetically modified cell therapies into clinical development, including one into pivotal trials. Previously, he was the founding President and CEO of Cylene Pharmaceuticals, a small molecule rational drug design company targeting secondary DNA structures to regulate oncogene expression. Tom received his B.A. in engineering from the University of Cambridge and MBA from Stanford Graduate School of Business, where he was an Arjay Miller scholar.